TY - JOUR
T1 - Management of Acute Lymphoblastic Leukemia in Older Adults
AU - Jammal, Nadya
AU - Kantarjian, Hagop M.
AU - Haddad, Fadi
AU - Jabbour, Elias J.
N1 - Funding Information:
Drs Jammal and Haddad have no disclosures to report. Dr Kantarjian has received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi-Sankyo, Immunogen, Jazz, Novar-tis, and Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision BioSciences, and Taiho Pharma Canada. Dr Jabbour has received research grants from Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, and Genentech.
Publisher Copyright:
© 2022, Millennium Medical Publishing, Inc.. All rights reserved.
PY - 2022/3
Y1 - 2022/3
N2 - Acute lymphoblastic leukemia, commonly known to affect the younger population, is a disease that is affecting the elderly in an increasing amount as the human life span continues to lengthen. Traditional cytotoxic agents are intolerable to elderly individuals owing to comorbidities, weakened immune systems, and organ dysfunction. Alternative agents and regimens are need-ed to allow for elderly patient to tolerate full cycles of therapy while providing complete and durable remissions. With the advent of targeted agents, such as monoclonal antibodies and bispecific T-cell engagers, a number of options have proven themselves to be effective in the elderly and optimal for tolerability. Here, we review and discuss the literature addressing regimens that use new agents, such as blinatumomab, inotuzumab ozogamicin, and vene-toclax, and those that use modified dosing strategies of traditional chemotherapy.
AB - Acute lymphoblastic leukemia, commonly known to affect the younger population, is a disease that is affecting the elderly in an increasing amount as the human life span continues to lengthen. Traditional cytotoxic agents are intolerable to elderly individuals owing to comorbidities, weakened immune systems, and organ dysfunction. Alternative agents and regimens are need-ed to allow for elderly patient to tolerate full cycles of therapy while providing complete and durable remissions. With the advent of targeted agents, such as monoclonal antibodies and bispecific T-cell engagers, a number of options have proven themselves to be effective in the elderly and optimal for tolerability. Here, we review and discuss the literature addressing regimens that use new agents, such as blinatumomab, inotuzumab ozogamicin, and vene-toclax, and those that use modified dosing strategies of traditional chemotherapy.
KW - Acute lymphoblastic leukemia (ALL)
KW - Elderly patients
KW - Older adults
UR - http://www.scopus.com/inward/record.url?scp=85126823479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126823479&partnerID=8YFLogxK
M3 - Article
C2 - 36607346
AN - SCOPUS:85126823479
SN - 1543-0790
VL - 20
SP - 161
EP - 168
JO - Clinical Advances in Hematology and Oncology
JF - Clinical Advances in Hematology and Oncology
IS - 3
ER -